Purchase Order 75N95025P00335
Award Date
8/7/25
Potential Completion Date
8/6/30
Potential Value
$533K
Federal Agency
National Institute on Drug Abuse
Awardee
Viralgen Vector Core SL
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Spain
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian federal agency, to Viralgen Vector Core SL, a for-profit organization located in Spain. The contract has a ceiling value of $120,050.00 and a completion date of March 30, 2026. The contract does not have a set-aside designation. The contract is for VIRALGEN VECTOR CORE SL:1516908 [25-000265], though details on the specific products or services being delivered...
This firm fixed-price purchase order was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to the University of Massachusetts Medical School (UMass Medical) for the delivery of 15 adeno-associated virus (AAV) serotype 9 preps expressing human codon-optimized mMut and MMAB donor sequences. The $46,379 contract supports NCATS' Platform Vector Gene Therapy project and will be used to test gene therapy strategies in disease model...
This firm-fixed price purchase order contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Expression Manufacturing LLC, a for-profit limited liability company, to provide 250 ml of concentrated lentiviral vector and conduct stability testing. The contract, valued at $648,968.00, has an ultimate completion date of August 31, 2029. This sole-source procurement was originally...
This is a firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Medigen, Inc., a biotechnology company specializing in vaccine development. The $815,000.00 contract is for laboratory and testing services. Medigen has previously received grants from NIAID totaling over $4 million to support R&D on novel live-attenuated vaccines. This contract does not have a...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services, to Geneimmune Biotechnology Corp, a for-profit Asian-Pacific American-owned biotechnology company based in Rockville, Maryland. The contract, valued at $98,347.40, is for DNA services including subcloning, mutagenesis, gene synthesis, and plasmid production to support NIAID's Vaccine Research Center's...
This is a firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Medigen, Inc., a biotechnology company that specializes in vaccine research, development, and manufacturing. The contract is for the production of Virus-Like Particles (VLPs) and has a total ceiling value of $28,280.00. This contract does not have a set-aside designation. Medigen, Inc. has previously...
This firm fixed-price purchase order for $18,204.88 was awarded by the Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse to Genscript USA Inc. to obtain cell lines utilizing CRISPR gene editing technology. Specifically, the contract calls for Genscript to generate knockout HEK293 and HepG2 cell lines of the MMAB and MUT genes to support studies for hereditary disorders of vitamin B12 and methylmalonic acid metabolism. No set-aside designation...
This firm fixed-price contract for $803,500.00 was awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), to Vector Biomed Inc. for the production and stability testing of clinical grade lentiviral vector. The services include manufacturing a minimum of 50mg of GMP/clinical grade transfer plasmid and 400ml of concentrated, GMP grade lentiviral vector, as well as performing stability testing...
This is a $120,000.00 firm fixed price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH), a civilian federal agency. The contract was awarded to Maxcyte, Inc., a commercial cell engineering company, to provide specialized laboratory equipment and technologies such as cell processing systems, electroporation and scalable transfection systems, and related consumables and maintenance services to support NIDA's...
The Department of Health and Human Services National Institutes of Health National Human Genome Research Institute awarded a firm fixed price purchase order contract to LI, Lina, a minority owned, self-certified small disadvantaged, woman-owned small business, for $400,100.00 to provide expertise in adeno-associated viral (AAV) gene therapy. The contract does not have a set-aside designation and is based on a pre-solicitation opportunity posted in November 2018 seeking highly specialized...